A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection.
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2010
At a glance
- Drugs Celgosivir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Carrus Capital Corporation
- 07 Apr 2010 BioWest Therapeutics added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
- 13 Jan 2009 New trial record.